Lala Kent Shares Her Take on Routine, Resilience, and Raising Healthy Kids in New Children's Health & Wellness Campaign
The campaign brings together pediatricians, mental health experts, educators, and parents to provide trusted guidance on the key issues shaping children's physical, emotional, and developmental well-being. Topics range from early screenings and sleep routines to healthy eating habits, mindfulness practices, and making mental health part of everyday parenting.
TV personality and entrepreneur Lala Kent leads the campaign's conversation as cover story feature, offering a raw and relatable look at modern motherhood. In her interview, Kent shares how becoming a parent reshaped her approach to health — from prioritizing sleep and movement to letting go of rigid expectations and focusing on what really matters. Kent also opens up about the challenges of co-parenting and the power of routine, emphasizing the importance of creating a home environment where children feel safe, supported, and empowered to be themselves. Her message to other parents: lean on your village, be kind to yourself, and don't be afraid to ask for help.
The print component of "Children's Health & Wellness" is distributed in today's edition of LA Times. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: https://www.futureofpersonalhealth.com/campaign/childrens-health/
This campaign was made possible with the support of Lala Kent, Jillian Michaels, Jennifer Anderson (@Kids.Eat.In.Color), Kacie Barnes (@MamaKnowsNutrition), Sarah Hoover, Jasmine Roth, American Academy of Pediatrics, Vaccinate Your Family, National Association of School Nurses, Partnership for a Healthier America, Project Sleep and features paid content from Pure Organic and CertiPUR-US.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lala-kent-shares-her-take-on-routine-resilience-and-raising-healthy-kids-in-new-childrens-health--wellness-campaign-302493584.html
SOURCE Mediaplanet
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock
Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ('ETST' or the 'Company'), a strategic holding company focused on acquiring and scaling high-potential businesses, today announced that its Board of Directors has approved a reduction of the Company's authorized shares of common stock from 350 million to 300 million. This strategic reduction in authorized shares of common stock is a direct reflection of the Board's confidence in the Company's current trajectory and its commitment to protecting long-term shareholder value. "This move by the Board of Directors aligns with our current goal of reducing the share count." said Giorgio R. Saumat, CEO of ETST. "It sends a clear signal to the investment community: we are confident in our financial health, strategic plan, and we are committed to preventing unnecessary shareholder dilution.' With the Company's outstanding share count at approximately 294.3 million, the Board determined that the previous authorization level of 350 million shares was no longer necessary given the Company's direction and financial planning. About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company's current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC ('Mister Meds'), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef. To learn more, please visit: LLC. based in Miami, Florida, is a fully licensed compounding pharmacy authorized to fulfill prescriptions in the following states and territories: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Wisconsin and Puerto Rico. RxCompound is actively pursuing licensure in the remaining U.S. states. To learn more please visit: MisterMeds, LLC. Mister Meds, acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound. To learn more please visit: Peaks Curative, LLC. Peaks is a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds. The platform operates in states where either pharmacy is licensed. Through the development of its own healthcare provider network, and ongoing licensure expansion for both pharmacies, Peaks aims to offer services nationwide. In addition, the company has recently expanded into the veterinary market through the acquisition of To learn more please visit: Las Villas Health Care, Inc. Las Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education—empowering you to take control of your health with confidence. To learn more please visit: LLC. Doconsultation was born with a passion to modernize the availability and delivery of home therapies. DOConsultations providers tailor a medication plan around your health and wellness goals and follow up with our patients to ensure results, while our partner pharmacies conveniently ship directly to your door. To learn more please visit: Avenvi, LLC. Avenvi is a diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company's ongoing $5 million share repurchase program. To learn more please visit: MagneChef MagneChef is a direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property. In addition, the company has recently expanded into the premium American-made BBQ tool brand market through the acquisition of BBQraft. To learn more please visit: About Earth Science Foundation, Inc. Earth Science Foundation Inc. a 501(c)(3) nonprofit organization incorporated on February 11, 2019, is the charitable arm of ETST. ESF accepts grants and donations to assist individuals who need financial support for prescription costs at both RxCompound and Mister Meds. SAFE HARBOR ACT: Forward-Looking Statements. Except for historical information, the matters discussed herein may be considered 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as 'expect,' 'expectation,' 'believe,' 'anticipate,' 'may,' 'could,' 'intend,' 'belief,' 'plan,' 'estimate,' 'target,' 'predict,' 'likely,' 'seek,' 'project,' 'model,' 'ongoing,' 'will,' 'should,' 'forecast,' 'outlook' or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company's actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Company Contact:Giorgio R. SaumatCEO and Chairman of the Board(305) 724-5684IR@
Yahoo
14 minutes ago
- Yahoo
Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ('Vivos' or the 'Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the three and six months ended June 30, 2025. Kirk Huntsman, Vivos' Chairman and Chief Executive Officer, stated, 'The second quarter of 2025 was a particularly important one in the history of Vivos. Building on our initiatives from 2024, we completed the key acquisition of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada. This acquisition marked a pivot in our core sales, marketing, and distribution model from one reliant on dentists alone for subscription and product revenue to a more comprehensive model that allows us to capture both OSA diagnostic and treatment revenue via more direct relationships with the patients who desperately need cutting-edge OSA treatments like ours.' 'This pivot was coupled with our investment in SCN plus a continued weaning off of our legacy enrollment revenue streams, and our weaker comparative second quarter results reflect this,' continued Mr. Huntsman. 'However, we are thrilled with what we are seeing out of SCN, as we recognized approximately $500,000 of diagnostic sleep testing services revenue over just twenty days from the June 10 closing to the end of the quarter.' 'Moreover, demand at SCN locations adapted to our Vivos model so far continues to exceed our current capacity, with patient appointments booked out for weeks and less than 40% of patients currently being served. This validates our belief in our new model, and so we are actively looking to scale this model in the quarters ahead with additional sleep center alliances or acquisitions. So, in sum, we believe we are ably navigating our strategic business model pivot, and we are confident that the future of Vivos is bright and that our strategic initiatives have positioned us for long-term growth,' concluded Mr. Huntsman. Second Quarter 2025 Financial and Operating Summary ● Revenue was $3.8 million for the second quarter of 2025 and $6.8 million for the six months ended June 30, 2025, compared to $4.1 million and $7.5 million for the three and six months ended June 30, 2024. The decline was expected and due to lower product and service revenue, resulting from Vivos' ongoing pivot in its sales, marketing and distribution model to focus on sleep center provider-based alliances and acquisitions, highlighted by Vivos' June 10, 2025 acquisition of SCN, the largest operator of medical sleep centers in Nevada (Vivos Closes SCN Acquisition); ● Gross profit was $2.1 million for the second quarter of 2025 and $3.6 million for the six months ended June 30, 2025, compared to $2.7 million and $4.6 million for the comparable periods in 2024, the decline attributable to the decrease in product and service revenue; ● Gross margin declined to 55% in the second quarter of 2025 from 65% in the second quarter of 2024. For the six months ended June 30, 2025, gross margin was 53% compared to 61% in the same period in 2024. This decrease was expected due to pricing discounts, shifts in product and service mix and the transition to Vivos' new sales, marketing and distribution model; ● Operating expenses for the second quarter ended June 30, 2025 were $7.0 million, a 52% increase compared to $4.6 million in the same period a year ago, reflecting increased spend in general and administrative owing to greater professional fees related to the equity and debt financings required for the acquisition and operation of SCN (much of which is expected to be non-recurring) and personnel and infrastructure costs associated with Vivos' integration of SCN. For the six months ended June 30, 2025, operating expenses were $12.4 million versus $10.3 million in the same period in 2024. ● The second quarter 2025 operating loss increased to $4.9 million compared to $1.9 million in the second quarter of 2024 and increased to $8.8 million for the six months ending June 30, 2025 from $5.7 million for the six months ended June 30, 2024. ● At June 30, 2025, cash and cash equivalents were $4.4 million and stockholders' equity was $4.6 million, compared to cash and equivalents of $6.2 million and stockholders' equity of $8.0 million respectively, as of December 31, 2024. Updated OSA Provider Management Model In addition to growth through acquisitions of medical sleep providers like SCN, Vivos is actively developing an updated sleep practice management model that it is implementing in situations where the sleep center or medical practice owners are not interested in being purchased, but are interested in making the full array of Vivos' OSA diagnostic and treatment options available to their patients. In furtherance of this initiative, on July 14, 2025, Vivos entered into its first such management agreement with MISleep Solutions LLC to provide our full suite of Vivos treatments and services to OSA patients at a joint location in Auburn Hills, Michigan (which is near Detroit). Consistent with its updated approach, Vivos owns a supermajority equity stake in the management services company, with the sleep doctors having minority ownership interests. Facilities to support these operations are currently being remodeled, with an estimated opening date in October 2025. Vivos is exploring similar arrangements in other states. Investor Call and 10-Q Filing Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos' strategic collaborations and their anticipated effect on near-term revenue growth and cash burn. To access Vivos' investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the replay is 1118815. The replay will be available until September 2, 2025 A live webcast of the conference call can be accessed on Vivos' website at An online archive of the webcast will be available at Vivos' website for 30 days following the call. In addition, further information on Vivos' financial results is included on the attached unaudited condensed consolidated balance sheets and statements of operations, and additional comments around Vivos' financial performance are provided in the Vivos' Quarterly Report on Form 10-Q for the three and six months ended June 30, 2025, which will be filed with the Securities and Exchange Commission ('SEC'). The full 10-Q report will be available on the SEC Filings section of the Investor Relations section of Vivos' website at About Vivos Therapeutics, Inc. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos' devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos' groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children. OSA affects over 1 billion people worldwide, yet 90% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it's closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes of OSA. Founded in 2016 and based in Littleton, CO, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to more thoroughly address the complex needs of OSA patients. Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to . For more information, visit Cautionary Note Regarding Forward-Looking Statements This press release and conference call referred to herein, including statements of the Company's management and other parties made in connection therewith, contain 'forward-looking statements' (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as 'may', 'would', 'should', 'expects', 'projects,' 'potential,' 'intends', 'plans', 'believes', 'anticipates', 'hopes', 'estimates', 'goal'. 'aim' and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to (i) the actual future impact of the SCN acquisition on Vivos' future revenues and results of operations and (ii) the anticipated benefits and potential expansion of Vivos' marketing and distribution model as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Actual results (including the actual results of the initiatives described herein on Vivos' future revenues and results of operations or the anticipated benefits of the Company's new marketing and distribution model described herein may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to successfully integrate SCN's business into its own or otherwise implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos' products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to acquire additional sleep centers practices on reasonable terms when needed, if at all, or maintain its Nasdaq listing, (v) market and other conditions that could impact Vivos' business or ability to obtain financing, and (vi) other risk factors described in Vivos' filings with the Securities and Exchange Commission ('SEC'). Vivos' filings can be obtained free of charge on the SEC's website at Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Media Inquiries: Bradford AmmanChief Financial Officer and Investor Relations Contactinvestors@ -Financial Tables Follow- VIVOS THERAPEUTICS Condensed Consolidated Balance Sheets (In Thousands, Except Per Share Amounts) June 30,2025 December 31,2024 Current assets Cash and cash equivalents $ 4,402 $ 6,260 Accounts receivable, net of allowance of $664 and $390, respectively 1,633 430 Prepaid expenses and other current assets 695 783 Total current assets 6,730 7,473 Long-term assets Goodwill 8,450 2,843 Property and equipment, net 5,129 3,350 Operating lease right-of-use asset 3,244 1,032 Intangible assets, net 2,225 370 Deposits and other 255 216 Total assets $ 26,033 $ 15,284 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,763 $ 1,098 Accrued expenses 2,302 2,234 Current portion of contract liabilities 480 896 Current portion of operating lease liability 654 477 Current portion of financing lease liability 55 - Current portion of debt 157 - Other current liabilities 1,015 273 Total current liabilities 6,426 4,978 Long-term liabilities Contract liabilities, net of current portion 5 97 Employee retention credit liability 2,904 1,220 Operating lease liability, net of current portion 2,814 1,035 Financing lease liability, net of current portion 141 - Debt, net of current portion 7,760 - Other liabilities 1,400 - Total liabilities 21,450 7,330 Commitments and contingencies Stockholders' equity Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; no shares issued and outstanding - - Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 7,324,807 shares as of June 30, 2025 and 5,889,520 shares as of December 31, 2024 - - Additional paid-in capital 117,647 112,141 Accumulated deficit (113,064 ) (104,187 ) Total stockholders' equity 4,583 7,954 Total liabilities and stockholders' equity $ 26,033 $ 15,284 VIVOS THERAPEUTICS Condensed Consolidated Statements of Operations(In Thousands, Except Per Share Amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue Product revenue $ 1,885 $ 1,975 $ 3,698 $ 3,650 Service revenue 1,935 2,079 3,137 3,823 Total revenue 3,820 4,054 6,835 7,473 Cost of sales (exclusive of depreciation and amortization shown separately below) 1,710 1,403 3,219 2,885 Gross profit 2,110 2,651 3,616 4,588 Operating expenses General and administrative 6,409 4,122 11,298 9,043 Sales and marketing 260 320 615 973 Depreciation and amortization 306 145 483 291 Total operating expenses 6,975 4,587 12,396 10,307 Operating loss (4,865 ) (1,936 ) (8,780 ) (5,719 ) Non-operating income (expense) Other expense (163 ) (22 ) (170 ) (24 ) Other income 15 28 73 51 Loss before income taxes (5,013 ) (1,930 ) (8,877 ) (5,692 ) Net loss $ (5,013 ) $ (1,930 ) $ (8,877 ) $ (5,692 ) Net loss per share (basic and diluted) $ (0.55 ) $ (0.60 ) $ (1.00 ) $ (2.06 ) Weighted average number of shares of Common Stock outstanding (basic and diluted) 9,087,202 3,228,363 8,842,604 2,768,934
Yahoo
14 minutes ago
- Yahoo
Walmart recalls frozen shrimp over potential radioactive contamination
Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia. The products could pose a 'potential health concern' for people exposed to low levels of Cesium-137 over time, FDA officials said. 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away,' FDA officials said in a statement. The risk from the recalled shrimp is 'quite low,' said Donald Schaffner, a food safety expert at Rutgers University. Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air. The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time. The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia. FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S. However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts. Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Solve the daily Crossword
